Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients.
Post-hematopoietic stem cell transplantation (HSCT) adenovirus infections were identified in 31 of 204 consecutive pediatric HSCT patients, 18 of whom had severe manifestations of infection. Cidofovir treatment led to clinical improvement in 8 of 10 patients with severe infection and to virologic clearance in 9 patients. In vitro susceptibility to cidofovir was demonstrated in 12 clinical adenovirus isolates. Cidofovir is a promising treatment option for this population.
Muller
William J
WJ
Department of Pediatrics, Division of Infectious Diseases, University of Washington, Seattle, USA. wmuller@u.washington.edu
Levin
Myron J
MJ
Shin
Young Kyoo
YK
Robinson
Christine
C
Quinones
Ralph
R
Malcolm
Janet
J
Hild
Elaine
E
Gao
Dexiang
D
Giller
Roger
R
D000256:Adenoviridae / Q000187:drug effects; D000258:Adenovirus Infections, Human / Q000188:drug therapy* / Q000209:etiology*; D000293:Adolescent; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D000077404:Cidofovir; D003596:Cytosine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D008826:Microbial Sensitivity Tests; D063065:Organophosphonates / Q000494:pharmacology / Q000627:therapeutic use*
D000998:Antiviral Agents; D063065:Organophosphonates; D003596:Cytosine; D000077404:Cidofovir